Streptogramins for the treatment of infections caused by Gram-positive pathogens

References

• Woodford N, Livermore DM. Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect. 2009;59(Suppl 1):S4–16.
   PubMed Web of Science ®Google Scholar
• David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev. 2010;23:616–687.
   PubMed Web of Science ®Google Scholar
• Zhang S, Sun X, Chang W, et al. Systematic review and meta-analysis of the epidemiology of vancomycin-intermediate and heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. PLoS One. 2015;10(8):e0136082.
   PubMed Web of Science ®Google Scholar
• Berlak N, Shany E, Ben-Shimol S, et al. Late onset sepsis: comparison between coagulase-negative staphylococci and other bacteria in the neonatal intensive care unit. Infect Dis. 2018;0:1–7.
   Google Scholar
• Bor DH, Woolhandler S, Nardin R, et al. Infective endocarditis in the U.S., 1998–2009: a nationwide study. Plos One. 2013;8(3):e60033.
   PubMed Web of Science ®Google Scholar
• von Eiff C, Peters G, Heilmann C. Pathogenesis of infections due to coagulase-negative staphylococci. Lancet Infect Dis. 2002;2:677–685.
   PubMed Web of Science ®Google Scholar
• O’Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist. 2015;8:217–230.
   PubMed Web of Science ®Google Scholar
• Wantuch PL, Avci FY. Current status and future directions of invasive pneumococcal diseases and prophylactic approaches to control them. Hum Vaccines Immunother. 2018;0:1–19.
   Google Scholar
• Chochua S, Metcalf BJ, Li Z, et al. Invasive serotype 35B pneumococci including an expanding serotype switch lineage, United States, 2015-2016. Emerg Infect Dis. 2017;23:922–930.
   PubMed Web of Science ®Google Scholar
• Devasahayam G, Scheld WM, Hoffman PS. Newer antibacterial drugs for a new century. Expert Opin Investig Drugs. 2010;19:215–234.
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U. Future antibiotics scenarios: is the tide starting to turn? Int J Antimicrob Agents. 2009;34:15–20.
   PubMed Web of Science ®Google Scholar
• Abbas M, Paul M, Huttner A. New and improved? A review of novel antibiotics for Gram-positive bacteria. Clin Microbiol Infect. 2017;23:697–703.
   PubMed Web of Science ®Google Scholar
• Cooper EC, Curtis N, Cranswick N, et al. Pristinamycin: old drug, new tricks? J Antimicrob Chemother. 2014;69:2319–2325.
   PubMed Web of Science ®Google Scholar
• Teng JC, Lingaratnam SM, Trubiano JA, et al. Oral pristinamycin for the treatment of resistant Gram-positive infections in patients with cancer: evaluation of clinical outcomes. Int J Antimicrob Agents. 2016;47:391–396.
   PubMed Web of Science ®Google Scholar
• Politano AD, Sawyer RG. NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA. Curr Opin Invest Drugs Lond Engl 2000. 2010;11:225–236.
   PubMed Web of Science ®Google Scholar
• Mast Y, Wohlleben W. Streptogramins – two are better than one! Int J Med Microbiol. 2014;304(1):44–50.
   PubMed Web of Science ®Google Scholar
• Bischoff KM, Zhang Y, Rich JO. Fate of virginiamycin through the fuel ethanol production process. World J Microbiol Biotechnol. 2016;32:76.
   PubMed Web of Science ®Google Scholar
• Mukhtar TA, Wright GD. Streptogramins, oxazolidinones, and other inhibitors of bacterial protein synthesis. Chem Rev. 2005;105:529–542.
   PubMed Web of Science ®Google Scholar
• Barrière JC, Berthaud N, Beyer D, et al. Recent developments in streptogramin research. Curr Pharm Des. 1998;4:155–180.
   PubMed Web of Science ®Google Scholar
• Canu A, Leclercq R. Overcoming bacterial resistance by dual target inhibition: the case of streptogramins. Curr Drug Targets Infect Disord. 2001;1: 215–225.
   PubMedGoogle Scholar
• Johnston NJ, Mukhtar TA, Wright GD. Streptogramin antibiotics: mode of action and resistance. Curr Drug Targets. 2002;3:335–344.
   PubMed Web of Science ®Google Scholar
• Cocito C, Di Giambattista M, Nyssen E, et al. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother. 1997;39(suppl 1):A:7–13.
   PubMedGoogle Scholar
• Vannuffel P, Cocito C. Mechanism of action of streptogramins and macrolides. Drugs. 1996;51(Suppl Supplement 1):20–30.
   PubMedGoogle Scholar
• Poehlsgaard J, Douthwaite S. The bacterial ribosome as a target for antibiotics. Nat Rev Microbiol. 2005;3:870–881.
   PubMed Web of Science ®Google Scholar
• Hansen JL, Moore PB, Steitz TA. Structures of five antibiotics bound at the peptidyl transferase center of the large ribosomal subunit. J Mol Biol. 2003;330:1061–1075.
   PubMed Web of Science ®Google Scholar
• Harms JM, Schlünzen F, Fucini P, et al. Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin. BMC Biol. 2004;2:4.
   PubMed Web of Science ®Google Scholar
• Tu D, Blaha G, Moore PB, et al. Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell. 2005;121(2):257–270.
   PubMed Web of Science ®Google Scholar
• Bouanchaud DH. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin. J Antimicrob Chemother. 1997;39(suppl 1):A:15–21.
   Google Scholar
• Lamb HM, Figgitt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999;58:1061–1097.
   PubMed Web of Science ®Google Scholar
• Speciale A, La Ferla K, Caccamo F, et al. Antimicrobial activity of quinupristin/dalfopristin, a new injectable streptogramin with a wide Gram-positive spectrum. Int J Antimicrob Agents. 1999;13:21–28.
   PubMed Web of Science ®Google Scholar
• Pankuch GA, Kelly LM, Lin G, et al. Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species. Antimicrob Agents Chemother. 2003;47:3270–3274.
   PubMed Web of Science ®Google Scholar
• Eliopoulos GM, Ferraro MJ, Wennersten CB, et al. In vitro activity of an oral streptogramin antimicrobial, XRP2868, against gram-positive bacteria. Antimicrob Agents Chemother. 2005;49:3034–3039.
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Citron DM, Merriam CV, et al. Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli. Antimicrob Agents Chemother. 2005;49:408–413.
   PubMed Web of Science ®Google Scholar
• Low DE, Nadler HL. A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus. J Antimicrob Chemother. 1997;39(Suppl A):53–58.
   PubMedGoogle Scholar
• Singh KV, Weinstock GM, Murray BE. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Antimicrob Agents Chemother. 2002;46:1845–1850.
   PubMed Web of Science ®Google Scholar
• Singh KV, Murray BE. Differences in the Enterococcus faecalis lsa locus that influence susceptibility to quinupristin-dalfopristin and clindamycin. Antimicrob Agents Chemother. 2005;49:32–39.
   PubMed Web of Science ®Google Scholar
• Dina J, Malbruny B, Leclercq R. Nonsense mutations in the lsa-like gene in Enterococcus faecalis isolates susceptible to lincosamides and Streptogramins A. Antimicrob Agents Chemother. 2003;47:2307–2309.
   PubMed Web of Science ®Google Scholar
• Bonfiglio G, Furneri PM. Novel streptogramin antibiotics. Expert Opin Investig Drugs. 2001;10:185–198.
   PubMed Web of Science ®Google Scholar
• Delgado G, Neuhauser MM, Bearden DT, et al. Quinupristin-dalfopristin: an overview. Pharmacotherapy. 2000;20(12):1469–1485.
   PubMed Web of Science ®Google Scholar
• Jensen JS, Cusini M, Gomberg M, et al. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol JEADV. 2016;30(10):1650–1656.
   PubMed Web of Science ®Google Scholar
• Bissessor M, Tabrizi SN, Twin J, et al. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015;60:1228–1236.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute MP. Performance standards for antimicrobial susceptibility testing, M100. 28th ed ed. S.l: Clinical and Laboratory Standards Institute; 2018.
   Google Scholar
• Clarebout G, Nativelle E, Bozdogan B, et al. Bactericidal activity of quinupristin-dalfopristin against strains of Staphylococcus aureus with the MLS(B) phenotype of resistance according to the erm gene type. Int J Antimicrob Agents. 2004;24:444–449.
   PubMed Web of Science ®Google Scholar
• John MA, Pletch C, Hussain Z. In vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci. J Antimicrob Chemother. 2002;50:933–938.
   PubMed Web of Science ®Google Scholar
• Fuchs PC, Barry AL, Brown SD. Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator. Antimicrob Agents Chemother. 2000;44:2880–2882.
   PubMed Web of Science ®Google Scholar
• Brown J, Freeman BB. Combining quinupristin/dalfopristin with other agents for resistant infections. Annals of Pharmacotherapy. 2001;10(4):185–198.
   Google Scholar
• Eliopoulos GM, Wennersten CB. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci. Antimicrob Agents Chemother. 2002;46:1319–1324.
   PubMed Web of Science ®Google Scholar
• Schwarz S, Shen J, Kadlec K, et al. Lincosamides, Streptogramins, phenicols, and pleuromutilins: mode of action and mechanisms of resistance. Cold Spring Harbor Perspect Med. 2016;6:a027037.
   PubMed Web of Science ®Google Scholar
• Hershberger E, Donabedian S, Konstantinou K, et al. Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis Off Publ Infect Dis Soc Am.. 2004;38: 92–98.
   PubMed Web of Science ®Google Scholar
• Roberts MC. Environmental macrolide-lincosamide-streptogramin and tetracycline resistant bacteria. Front Microbiol. 2011;2:40.
   PubMed Web of Science ®Google Scholar
• Roberts MC. Update on macrolide-lincosamide-streptogramin, ketolide, and oxazolidinone resistance genes. FEMS Microbiol Lett. 2008;282:147–159.
   PubMed Web of Science ®Google Scholar
• Hays C, Lienhard R, Auzou M, et al. Erm(X)-mediated resistance to macrolides, lincosamides and streptogramins in Actinobaculum schaalii. J Antimicrob Chemother. 2014;69:2056–2060.
   PubMed Web of Science ®Google Scholar
• Wipf JRK, Schwendener S, Perreten V. The novel macrolide-lincosamide-streptogramin B resistance gene erm(44) is associated with a prophage in Staphylococcus xylosus. Antimicrob Agents Chemother. 2014;58:6133–6138.
   PubMed Web of Science ®Google Scholar
• Wipf JRK, Schwendener S, Nielsen JB, et al. The new macrolide-lincosamide-streptogramin B resistance gene erm(45) is located within a genomic island in Staphylococcus fleurettii. Antimicrob Agents Chemother. 2015;59:3578–3581.
   PubMed Web of Science ®Google Scholar
• Wipf JRK, Riley MC, Kania SA, et al. New macrolide-lincosamide-streptogramin B resistance gene erm(48) on the novel plasmid pJW2311 in Staphylococcus xylosus. Antimicrob Agents Chemother. 2017;61:e00066–17.
   PubMed Web of Science ®Google Scholar
• Cattoir V, Merabet L, Legrand P, et al. Emergence of a Streptococcus pneumoniae isolate resistant to streptogramins by mutation in ribosomal protein L22 during pristinamycin therapy of pneumococcal pneumonia. J Antimicrob Chemother. 2007;59:1010–1012.
   PubMed Web of Science ®Google Scholar
• Sharkey LKR, Edwards TA, O’Neill AJ. ABC-F Proteins mediate antibiotic resistance through ribosomal protection. mBio. 2016;7:e01975.
   PubMed Web of Science ®Google Scholar
• Kehrenberg C, Schwarz S. Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob Agents Chemother. 2006;50:1156–1163.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang W, Wang J, et al. Distribution of the multidrug resistance gene cfr in Staphylococcus species isolates from swine farms in China. Antimicrob Agents Chemother. 2012;56:1485–1490.
   PubMed Web of Science ®Google Scholar
• He T, Wang Y, Schwarz S, et al. Genetic environment of the multi-resistance gene cfr in methicillin-resistant coagulase-negative staphylococci from chickens, ducks, and pigs in China. Int J Med Microbiol IJMM.. 2014;304: 257–261.
   PubMed Web of Science ®Google Scholar
• Toh S-M, Xiong L, Arias CA, et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol. 2007;64:1506–1514.
   PubMed Web of Science ®Google Scholar
• Witte W, Cuny C. Emergence and spread of cfr-mediated multiresistance in staphylococci: an interdisciplinary challenge. Future Microbiol. 2011;6:925–931.
   PubMed Web of Science ®Google Scholar
• Cai JC, Hu YY, Zhou HW, et al. Dissemination of the same cfr-carrying plasmid among methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococcal isolates in China. Antimicrob Agents Chemother. 2015;59:3669–3671.
   PubMed Web of Science ®Google Scholar
• Kehrenberg C, Schwarz S, Jacobsen L, et al. A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503. Mol Microbiol. 2005;57:1064–1073.
   PubMed Web of Science ®Google Scholar
• Long KS, Poehlsgaard J, Kehrenberg C, et al. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother. 2006;50:2500–2505.
   PubMed Web of Science ®Google Scholar
• Schwarz S, Werckenthin C, Kehrenberg C. Identification of a plasmid-borne chloramphenicol-florfenicol resistance gene in Staphylococcus sciuri. Antimicrob Agents Chemother. 2000;44:2530–2533.
   PubMed Web of Science ®Google Scholar
• Murina V, Kasari M, Hauryliuk V, et al. Antibiotic resistance ABCF proteins reset the peptidyl transferase centre of the ribosome to counter translational arrest. Nucleic Acids Res. 2018;46:3753–3763.
   PubMed Web of Science ®Google Scholar
• Isnard C, Malbruny B, Leclercq R, et al. Genetic basis for in vitro and in vivo resistance to lincosamides, streptogramins A, and pleuromutilins (LSAP phenotype) in Enterococcus faecium. Antimicrob Agents Chemother. 2013;57:4463–4469.
   PubMed Web of Science ®Google Scholar
• El Solh N, Allignet J. Staphylococcal resistance to streptogramins and related antibiotics. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother. 1998;1:169–175.
   Google Scholar
• Leclercq R, Nantas L, Soussy CJ, et al. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J Antimicrob Chemother. 1992;30(Suppl A):67–75.
   PubMedGoogle Scholar
• Dupuis M, Leclercq R. Activity of a new oral streptogramin, XRP2868, against gram-positive cocci harboring various mechanisms of resistance to streptogramins. Antimicrob Agents Chemother. 2006;50:237–242.
   PubMed Web of Science ®Google Scholar
• Fantin B, Leclercq R, Merlé Y, et al. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob Agents Chemother. 1995;39:400–405.
   PubMed Web of Science ®Google Scholar
• Fantin B, Leclercq R, Garry L, et al. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrob Agents Chemother. 1997;41:931–935.
   PubMed Web of Science ®Google Scholar
• Entenza JM, Drugeon H, Glauser MP, et al. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob Agents Chemother. 1995;39:1419–1424.
   PubMed Web of Science ®Google Scholar
• Batard E, Jacqueline C, Boutoille D, et al. Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant Staphylococcus aureus: experimental rabbit endocarditis study. Antimicrob Agents Chemother. 2002;46:2174–2178.
   PubMed Web of Science ®Google Scholar
• Wang S, Guo Y, Lv J, et al. Characteristic of Enterococcus faecium clinical isolates with quinupristin/dalfopristin resistance in China. BMC Microbiol. 2016;16:246.
   PubMed Web of Science ®Google Scholar
• Thal LA, Zervos MJ. Occurrence and epidemiology of resistance to virginiamycin and streptogramins. J Antimicrob Chemother. 1999;43:171–176.
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis. 2003;36:473–481.
   PubMed Web of Science ®Google Scholar
• Sader HS, Watters AA, Fritsche TR, et al. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis. 2007;7:29.
   PubMed Web of Science ®Google Scholar
• Deshpande LM, Fritsche TR, Moet GJ, et al. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007;58:163–170.
   PubMed Web of Science ®Google Scholar
• Werner G, Klare I, Witte W. Molecular analysis of streptogramin resistance in enterococci. Int J Med Microbiol IJMM. 2002;292:81–94.
   PubMed Web of Science ®Google Scholar
• Shariati A, Dadashi M, Chegini Z, et al. The global prevalence of daptomycin, tigecycline, quinupristin/dalfopristin, and linezolid-resistant Staphylococcus aureus and coagulase-negative staphylococci strains: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2020;9:56.
   PubMed Web of Science ®Google Scholar
• Leclercq R, Soussy CJ, Weber P, et al. Groupe d’Etude Multicentrique. [In vitro activity of the pristinamycin against the isolated staphylococci in the french hospitals in 1999-2000]. Pathol Biol. 2003;51::400–404.
   PubMed Web of Science ®Google Scholar
• Fritsche TR, Sader HS, Jones RN. Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002). Diagn Microbiol Infect Dis. 2003;47:435–440.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Sader HS, Deshpande L, et al. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn Microbiol Infect Dis. 2008;60:433–436.
   PubMed Web of Science ®Google Scholar
• Flamm RK, Farrell DJ, Mendes RE, et al. LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). Diagn Microbiol Infect Dis. 2012;74:54–61.
   PubMed Web of Science ®Google Scholar
• Malbruny B, Werno AM, Anderson TP, et al. A new phenotype of resistance to lincosamide and streptogramin A-type antibiotics in Streptococcus agalactiae in New Zealand. J Antimicrob Chemother. 2004;54:1040–1044.
   PubMed Web of Science ®Google Scholar
• Hawkins PA, Law CS, Metcalf BJ, et al. Cross-resistance to lincosamides, streptogramins A and pleuromutilins in Streptococcus agalactiae isolates from the USA. J Antimicrob Chemother. 2017;72:1886–1892.
   PubMed Web of Science ®Google Scholar
• Batah J, Varon E. Rapport d’activité 2017 du Centre National de Référence des Pneumocoques. 2017;84. https://cnr-pneumo.com/docman/rapports/21-cnrp2017/file.
   Google Scholar
• Koechlin C, Kempf JF, Jehl F, et al. Single oral dose pharmacokinetics of the two main components of pristinamycin in humans. J Antimicrob Chemother. 1990;25:651–656.
   PubMed Web of Science ®Google Scholar
• Bearden DT. Clinical pharmacokinetics of quinupristin/dalfopristin. Clin Pharmacokinet. 2004;43:239–252.
   PubMed Web of Science ®Google Scholar
• Fantin B, Leclercq R, Ottaviani M, et al. In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob Agents Chemother. 1994;38:432–437.
   PubMed Web of Science ®Google Scholar
• Pessey JJ. [Pristinamycin use in the treatment of acute maxillary sinusitis in adults]. Med Mal Infect. 2008;38:9–11.
   PubMed Web of Science ®Google Scholar
• Gehanno P, Berche P, Hercot O,D, et al. [Efficiency of a four-day course of pristinamycin compared to a five-day course of cefuroxime axetil for acute bacterial maxillary sinusitis in adult outpatients]. Med Mal Infect. 2004;34:293–302.
   PubMed Web of Science ®Google Scholar
• Trémolières F, Mayaud C, Mouton Y, et al. [Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults]. Pathol Biol (Paris). 2005;53: 503–510.
   PubMed Web of Science ®Google Scholar
• Poirier R, Chardon H, Beraud A, et al. [Efficacy and tolerability of pristinamycin vs amoxicillin-clavulanic acid combination in the treatment of acute community-acquired pneumonia in hospitalized adults]. Rev Pneumol Clin. 1997;53:325–331.
   PubMedGoogle Scholar
• Léophonte P, Chidiac C, Drugeon HB, et al. [Treatment of exacerbations of chronic obstructive pulmonary disease with pristinamycin]. Rev Mal Respir. 2004;21:261–271.
   PubMed Web of Science ®Google Scholar
• Bernard P, Vaillant L, Martin C, et al. [Pristinamycin versus oxacillin in the treatment of superficial pyoderma. A multicenter randomized study in 293 outpatients]. Ann Dermatol Venereol. 1997;124::384–389.
   PubMed Web of Science ®Google Scholar
• Bernard P, Chosidow O, Vaillant L. French erysipelas study group. oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial. BMJ. 2002;325:864.
   PubMedGoogle Scholar
• Bernard P, Risse L, Bonnetblanc JM. [Pristinamycin in the treatment of acute bacterial dermohypodermitis in adults. An open study of 42 patients]. Ann Dermatol Venereol. 1996;123::16–20.
   PubMed Web of Science ®Google Scholar
• Chosidow O, Bernard P, Berbis P, et al. Cloxacillin versus pristinamycin for superficial pyodermas: a randomized, open-label, non-inferiority study. Dermatol Basel Switz. 2005;210:370–374.
   PubMed Web of Science ®Google Scholar
• Ng J, Gosbell IB. Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp. J Antimicrob Chemother. 2005;55:1008–1012.
   PubMed Web of Science ®Google Scholar
• Valour F, Boibieux A, Karsenty J, et al. Pristinamycin in the treatment of MSSA bone and joint infection. J Antimicrob Chemother. 2016;71:1063–1070.
   PubMed Web of Science ®Google Scholar
• Reid AB, Daffy JR, Stanley P, et al. Use of pristinamycin for infections by gram-positive bacteria: clinical experience at an Australian hospital. Antimicrob Agents Chemother. 2010;54:3949–3952.
   PubMed Web of Science ®Google Scholar
• Ruparelia N, Atkins BL, Hemingway J, et al. Pristinamycin as adjunctive therapy in the management of Gram-positive multi-drug resistant organism (MDRO) osteoarticular infection. J Infect. 2008;57: 191–197.
   PubMed Web of Science ®Google Scholar
• Dancer SJ, Robb A, Crawford A, et al. Oral streptogramins in the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. J Antimicrob Chemother. 2003;51:731–735.
   PubMed Web of Science ®Google Scholar
• Bradshaw CS, Jensen JS, Waites KB. New horizons in Mycoplasma genitalium treatment. J Infect Dis. 2017;216:S412–S419.
   PubMed Web of Science ®Google Scholar
• Sethi S, Zaman K, Jain N. Mycoplasma genitalium infections: current treatment options and resistance issues. Infect Drug Resist.. 2017;10: 283–292.
   PubMed Web of Science ®Google Scholar
• Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the synercid emergency-use study group. J Antimicrob Chemother. 2000;46:775–784.
   PubMed Web of Science ®Google Scholar
• Raad I, Bompart F, Hachem R. Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol.. 1999;18: 199–202.
   PubMed Web of Science ®Google Scholar
• Linden PK, Moellering RC, Wood CA, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis Off Publ Infect Dis Soc Am.. 2001;33:1816–1823.
   PubMed Web of Science ®Google Scholar
• Raad I, Hachem R, Hanna H, et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother. 2004;53:646–649.
   PubMed Web of Science ®Google Scholar
• Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother. 1999;44:251–261.
   PubMed Web of Science ®Google Scholar
• Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid skin and skin structure infection group. J Antimicrob Chemother. 1999;44:263–273.
   PubMed Web of Science ®Google Scholar
• Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial pneumonia group. Am J Respir Crit Care Med. 2000;161:753–762.
   PubMed Web of Science ®Google Scholar
• Loeffler AM, Drew RH, Perfect JR, et al. Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients. Pediatr Infect Dis J. 2002;21:950–956.
   PubMed Web of Science ®Google Scholar
• Habib G, Lancellotti P, Antunes MJ, et al. ESC Guidelines for the management of infective endocarditis. Eur Heart J. 2015;2015(36):3075–3128.
   Google Scholar
• Denis Prevot M, Thillard EM, Walther J, et al. Pristinamycin-induced arthralgia and myalgia: analysis of the French pharmacovigilance database. Med Mal Infect. 2018;48:58–62.
   PubMed Web of Science ®Google Scholar